Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.

Gao JL, Owusu-Ansah A, Paun A, Beacht K, Yim E, Siwicki M, Yang A, Liu Q, McDermott DH, Murphy PM.

JCI Insight. 2019 Nov 5. pii: 132140. doi: 10.1172/jci.insight.132140. [Epub ahead of print]

2.

Abnormal Newborn Screen in a WHIM Syndrome Infant.

Evans MO 2nd, McDermott DH, Murphy PM, Petersen MM.

J Clin Immunol. 2019 Nov;39(8):839-841. doi: 10.1007/s10875-019-00686-5. Epub 2019 Sep 6. No abstract available.

PMID:
31493092
3.

Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient.

McDermott DH, Heusinkveld LE, Zein WM, Sen HN, Marquesen MM, Parta M, Rosenzweig SD, Fahle GA, Keller MD, Wiley HE, Murphy PM.

Version 2. F1000Res. 2019 Jan 2 [revised 2019 Jan 1];8:2. doi: 10.12688/f1000research.16825.2. eCollection 2019.

4.

WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM.

J Clin Immunol. 2019 Aug;39(6):532-556. doi: 10.1007/s10875-019-00665-w. Epub 2019 Jul 16.

PMID:
31313072
5.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

McDermott DH, Murphy PM.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646. No abstract available.

PMID:
30995388
6.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

7.

WHIM syndrome: Immunopathogenesis, treatment and cure strategies.

McDermott DH, Murphy PM.

Immunol Rev. 2019 Jan;287(1):91-102. doi: 10.1111/imr.12719. Review.

PMID:
30565238
8.

Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB.

mSphere. 2018 Dec 12;3(6). pii: e00645-18. doi: 10.1128/mSphereDirect.00645-18.

9.

Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

Gao JL, Yim E, Siwicki M, Yang A, Liu Q, Azani A, Owusu-Ansah A, McDermott DH, Murphy PM.

J Clin Invest. 2018 Aug 1;128(8):3312-3318. doi: 10.1172/JCI120375. Epub 2018 Jun 25.

10.

Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.

Liu Q, Li Z, Y Yang A, Gao JL, S Velez D, J Cho E, McDermott DH, Murphy PM.

J Clin Immunol. 2018 Jan;38(1):77-87. doi: 10.1007/s10875-017-0457-8. Epub 2017 Nov 24.

11.

Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.

Heusinkveld LE, Yim E, Yang A, Azani AB, Liu Q, Gao JL, McDermott DH, Murphy PM.

Expert Opin Orphan Drugs. 2017;5(10):813-825. doi: 10.1080/21678707.2017.1375403. Epub 2017 Sep 25.

12.

WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).

Liu Q, Pan C, Lopez L, Gao J, Velez D, Anaya-O'Brien S, Ulrick J, Littel P, Corns JS, Ellenburg DT, Malech HL, Murphy PM, McDermott DH.

J Clin Immunol. 2016 May;36(4):397-405. doi: 10.1007/s10875-016-0276-3. Epub 2016 Apr 8.

PMID:
27059040
13.

Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantation.

McDermott DH, Gao JL, Murphy PM.

Rare Dis. 2015 Aug 11;3(1):e1073430. doi: 10.1080/21675511.2015.1073430. eCollection 2015.

14.

Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes.

Jindra PT, Conway SE, Ricklefs SM, Porcella SF, Anzick SL, Haagenson M, Wang T, Spellman S, Milford E, Kraft P, McDermott DH, Abdi R.

Biol Blood Marrow Transplant. 2016 Jan;22(1):27-36. doi: 10.1016/j.bbmt.2015.08.037. Epub 2015 Sep 5.

15.

CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice.

Liu Q, Li Z, Gao JL, Wan W, Ganesan S, McDermott DH, Murphy PM.

Eur J Immunol. 2015 Jun;45(6):1855-67. doi: 10.1002/eji.201445245. Epub 2015 Apr 24.

16.

Chromothriptic cure of WHIM syndrome.

McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C, Jacobs P, Velez D, Yim E, Bryke CR, Hsu N, Dai Z, Marquesen MM, Stregevsky E, Kwatemaa N, Theobald N, Long Priel DA, Pittaluga S, Raffeld MA, Calvo KR, Maric I, Desmond R, Holmes KL, Kuhns DB, Balabanian K, Bachelerie F, Porcella SF, Malech HL, Murphy PM.

Cell. 2015 Feb 12;160(4):686-699. doi: 10.1016/j.cell.2015.01.014. Epub 2015 Feb 5.

17.

The effect of Rho kinase inhibition on long-term keratinocyte proliferation is rapid and conditional.

Chapman S, McDermott DH, Shen K, Jang MK, McBride AA.

Stem Cell Res Ther. 2014 Apr 28;5(2):60. doi: 10.1186/scrt449.

18.

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DA, Merideth MA, Giuntoli RL, Evbuomwan MO, Littel P, Marquesen MM, Hilligoss D, DeCastro R, Grimes GJ, Hwang ST, Pittaluga S, Calvo KR, Stratton P, Cowen EW, Kuhns DB, Malech HL, Murphy PM.

Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12.

19.

A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus.

Pastrana DV, Fitzgerald PC, Phan GQ, Raiji MT, Murphy PM, McDermott DH, Velez D, Bliskovsky V, McBride AA, Buck CB.

Genome Announc. 2013 Oct 24;1(5). pii: e00812-13. doi: 10.1128/genomeA.00812-13.

20.

Complete genome sequence of a tenth human polyomavirus.

Buck CB, Phan GQ, Raiji MT, Murphy PM, McDermott DH, McBride AA.

J Virol. 2012 Oct;86(19):10887. doi: 10.1128/JVI.01690-12.

21.

Unexpected developments in immune organs in WHIM syndrome.

Murphy PM, McDermott DH.

Blood. 2012 Jun 14;119(24):5610-2. doi: 10.1182/blood-2012-04-420752. No abstract available.

PMID:
22700690
22.

WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Liu Q, Chen H, Ojode T, Gao X, Anaya-O'Brien S, Turner NA, Ulrick J, DeCastro R, Kelly C, Cardones AR, Gold SH, Hwang EI, Wechsler DS, Malech HL, Murphy PM, McDermott DH.

Blood. 2012 Jul 5;120(1):181-9. doi: 10.1182/blood-2011-12-395608. Epub 2012 May 17.

23.

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, Filho JO, Priel DA, Kelly C, Garofalo M, Littel P, Marquesen MM, Hilligoss D, Decastro R, Fleisher TA, Kuhns DB, Malech HL, Murphy PM.

Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2.

24.

Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice.

Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM.

Circ Res. 2011 Aug 5;109(4):374-81. doi: 10.1161/CIRCRESAHA.111.242578. Epub 2011 Jun 16.

25.

AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.

McDermott DH, Lopez J, Deng F, Liu Q, Ojode T, Chen H, Ulrick J, Kwatemaa N, Kelly C, Anaya-O'Brien S, Garofalo M, Marquesen M, Hilligoss D, DeCastro R, Malech HL, Murphy PM.

J Cell Mol Med. 2011 Oct;15(10):2071-81. doi: 10.1111/j.1582-4934.2010.01210.x.

26.

Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.

McDermott DH, De Ravin SS, Jun HS, Liu Q, Priel DA, Noel P, Takemoto CM, Ojode T, Paul SM, Dunsmore KP, Hilligoss D, Marquesen M, Ulrick J, Kuhns DB, Chou JY, Malech HL, Murphy PM.

Blood. 2010 Oct 14;116(15):2793-802. doi: 10.1182/blood-2010-01-265942. Epub 2010 Jul 8.

27.

Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome.

Jun HS, Lee YM, Cheung YY, McDermott DH, Murphy PM, De Ravin SS, Mansfield BC, Chou JY.

Blood. 2010 Oct 14;116(15):2783-92. doi: 10.1182/blood-2009-12-258491. Epub 2010 May 24.

28.

Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.

McDermott DH, Conway SE, Wang T, Ricklefs SM, Agovi MA, Porcella SF, Tran HT, Milford E, Spellman S, Abdi R.

Blood. 2010 Mar 18;115(11):2311-8. doi: 10.1182/blood-2009-08-237768. Epub 2010 Jan 12.

29.

CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.

Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM.

J Infect Dis. 2010 Jan 15;201(2):178-85. doi: 10.1086/649426.

30.

Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man.

Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM.

PLoS Pathog. 2009 Feb;5(2):e1000321. doi: 10.1371/journal.ppat.1000321. Epub 2009 Feb 27.

31.

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.

Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, McDermott DH, Murphy PM.

J Infect Dis. 2008 Jan 15;197(2):262-5. doi: 10.1086/524691.

PMID:
18179388
32.

Role of beta3 integrin in acute renal allograft rejection in humans.

Chandrakantan A, McDermott DH, Tran HT, Jurewicz M, Gallon L, Gaston R, Milford E, Abdi R.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1268-73. Epub 2007 Oct 10.

33.

Assessment of cumulative evidence on genetic associations: interim guidelines.

Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JP, McCarthy MI, McDermott DH, Page GP, Rebbeck TR, Seminara D, Khoury MJ.

Int J Epidemiol. 2008 Feb;37(1):120-32. Epub 2007 Sep 26. Review.

PMID:
17898028
34.

Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation.

Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R.

J Am Soc Nephrol. 2007 Apr;18(4):1093-102. Epub 2007 Feb 28.

35.

CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection.

Lim JK, Glass WG, McDermott DH, Murphy PM.

Trends Immunol. 2006 Jul;27(7):308-12. Epub 2006 Jun 5. Review.

PMID:
16753343
36.

CCR5 deficiency increases risk of symptomatic West Nile virus infection.

Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM.

J Exp Med. 2006 Jan 23;203(1):35-40. Epub 2006 Jan 17.

37.

CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study.

McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr, Larson MG, Vasan RS, Hirschhorn JN, O'Donnell CJ, Murphy PM, Benjamin EJ.

Circulation. 2005 Aug 23;112(8):1113-20.

PMID:
16116069
38.

Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms.

Barlic J, McDermott DH, Merrell MN, Gonzales J, Via LE, Murphy PM.

J Biol Chem. 2004 Nov 19;279(47):48520-34. Epub 2004 Sep 3.

39.

Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.

Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, Murphy PM, Alkhatib G.

J Virol. 2004 Mar;78(5):2277-87.

40.

Chemokines and diseases.

Dong VM, McDermott DH, Abdi R.

Eur J Dermatol. 2003 May-Jun;13(3):224-30. Review.

PMID:
12804978
41.

Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans.

McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM.

J Clin Invest. 2003 Apr;111(8):1241-50.

42.

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ.

Gastroenterology. 2003 Feb;124(2):352-60. Erratum in: Gastroenterology. 2003 Apr;124(4):1168..

PMID:
12557141
43.

Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation.

Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH.

J Am Soc Nephrol. 2002 Mar;13(3):754-8.

44.

Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R.

Sahagun-Ruiz A, Colla JS, Juhn J, Gao JL, Murphy PM, McDermott DH.

Genes Immun. 2001 Oct;2(6):335-42.

45.

Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.

McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM.

Circ Res. 2001 Aug 31;89(5):401-7.

PMID:
11532900
46.

Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue.

Malkevitch N, McDermott DH, Yi Y, Grivel JC, Schols D, De Clercq E, Murphy PM, Glushakova S, Collman RG, Margolis L.

Virology. 2001 Mar 15;281(2):239-47.

47.

Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease.

Moatti D, Faure S, Fumeron F, Amara Mel-W, Seknadji P, McDermott DH, Debré P, Aumont MC, Murphy PM, de Prost D, Combadière C.

Blood. 2001 Apr 1;97(7):1925-8.

PMID:
11264153
48.

Genetic polymorphism in CX3CR1 and risk of HIV disease.

McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadière C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM.

Science. 2000 Dec 15;290(5499):2031. No abstract available.

49.

Chemokines and their receptors in infectious disease.

McDermott DH, Murphy PM.

Springer Semin Immunopathol. 2000;22(4):393-415. Review. No abstract available.

PMID:
11155443
50.

Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study.

McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH, Murphy PM.

AIDS. 2000 Dec 1;14(17):2671-8.

PMID:
11125885

Supplemental Content

Loading ...
Support Center